nach oben

Erschienen in:

01.03.2010 | Dementias - Original Article

BuChE K variant is decreased in Alzheimer’s disease not in fronto-temporal dementia

verfasst von: Alessandra Bizzarro, V. Guglielmi, R. Lomastro, A. Valenza, A. Lauria, C. Marra, M. C. Silveri, F. D. Tiziano, C. Brahe, C. Masullo

Erschienen in: Journal of Neural Transmission | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Alzheimer’s disease (AD) is characterized by a significant reduction in AcetylCholinesterase and an increase in ButyrylCholinesterase (BuChE) activity. The existence of polymorphic regions on the BuChE gene has been previously described; the most frequently found polymorphism is the so-called K variant, which leads to a 30% decreased enzymatic activity. Different studies reported a positive association between K variant and AD, strongest among late-onset AD and Apolipoprotein E (APOE) e4 carriers. We analyzed APOE and BuChE polymorphisms in 167 AD and 59 fronto-temporal dementia (FTD) patients compared with 129 healthy controls (HC). We reported a significantly lower frequency of the BuChE K variant in AD compared with HC and FTD and a significant increased frequency of the K variant in FTD. These results are in agreement with the known increase of the BuChE activity in AD and support the evidence of different molecular pathways involved in the pathogenesis of AD and FTD.

Alvarez A, Opazo C, Alarcón R, Garrido J, Inestrosa NC (1997) Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. J Mol Biol 272:348–361CrossRefPubMed

Alvarez-Arcaya A, Combarros O, Llorca J, Sánchez-Guerra M, Berciano J, Fernández-Viadero C, Peña N (2000) The butyrylcholinesterase K variant is a protective factor for sporadic Alzheimer’s disease in women. Acta Neurol Scand 102:350–353CrossRefPubMed

Ballard C, Morris C, Kalaria R, McKeith I, Perry R, Perry E (2005) The K variant of the butyrylcholinesterase gene is associated with reduced phosphorylation of tau in dementia patients. Dement Geriatr Cogn Disord 19:357–360CrossRefPubMed

Bartels CF, Jensen FS, Lockridge O, van der Spek AF, Rubinstein HM, Lubrano T, La Du BN (1992) DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet 50:1086–1103PubMed

Blacker D, Haines JL, Rodes L, Terwedow H, Go RC, Harrell LE, Perry RT, Bassett SS, Chase G, Meyers D, Albert MS, Tanzi R (1997) ApoE-4 and age at onset of Alzheimer’s disease: the NIMH genetics initiative. Neurology 48:139–147PubMed

Blesa R, Bullock R, He Y, Bergman H, Gambina G, Meyer J, Rapatz G, Nagel J, Lane R (2006) Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer’s disease. Pharmacogenet Genomics 16:771–774CrossRefPubMed

Combarros O, Riancho JA, Arozamena J, Mateo I, Llorca J, Infante J, Sánchez-Juan P, Zarrabeitia MT, Berciano J (2007) Interaction between estrogen receptor-alpha and butyrylcholinesterase genes modulates Alzheimer’s disease risk. J Neurol 254:1290–1292CrossRefPubMed

Darreh-Shori T, Brimijoin S, Kadir A, Almkvist O, Nordberg A (2006) Differential CSF butyrylcholinesterase levels in Alzheimer’s disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism. Neurobiol Dis 24:326–333CrossRefPubMed

Darreh-Shori T, Modiri N, Blennow K, Baza S, Kamil C, Ahmed H, Andreasen N, Nordberg A (2009) The apolipoprotein E varepsilon4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase. Neurobiol Aging (epub ahead of print)

Darvesh S, Hopkins DA (2003) Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human talamus. J Comp Neurol 463:25–43CrossRefPubMed

Déniz-Naranjo MC, Muñoz-Fernández C, Alemany-Rodríguez MJ, del Carmen Pérez-Vieitez M, Aladro-Benito Y, Irurita-Latasa J, Sánchez-García F (2007) Butyrylcholinesterase. ApoE and Alzheimer’s disease in a population from the Canary Islands (Spain). Neurosci Lett 427:34–38CrossRefPubMed

Diamant S, Podoly E, Friedler A, Ligumsky H, Livnah O, Soreq H (2006) Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc Natl Acad Sci USA 103:8628–8633CrossRefPubMed

Duara R, Barker WW, Lopez-Alberola R, Loewenstein DA, Grau LB, Gilchrist D, Sevush S, St George-Hyslop S (1996) Alzheimer’s disease: interaction of apolipoprotein E genotype, family history of dementia, gender, education, ethnicity, and age of onset. Neurology 46:1575–1579PubMed

Geula C, Mesulam M-M (1989) Cortical cholinergic fibres in aging and Alzheimer’s Disease: a morphometric study. Neuroscience 33:469–481CrossRefPubMed

Ghebremedhin E, Thal DR, Schultz C, Braak H (2002) Age-dependent association between butyrylcholinesterase K-variant and Alzheimer Disease-related neuropathology in human brains. Neurosci Lett 320:25–28CrossRefPubMed

Gómez-Ramos P, Bouras C, Morán MA (1994) Ultrastructural localization of butyrylcholinesterase on neurofibrillary degeneration sites in the brains of aged and Alzheimer’s disease patients. Brain Res 640:17–24CrossRefPubMed

Grubber JM, Saunders AM, Crane-Gatherum AR, Scott WK, Martin ER, Haynes CS, Conneally PM, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1999) Analysis of association between Alzheimer disease and the K variant of butyrylcholinesterase (BCHE-K). Neurosci Lett 269:115–119CrossRefPubMed

Hiltunen M, Mannermaa A, Helisalmi S, Koivisto A, Lehtovirta M, Ryynanen P Sr, Soininen H (1998) Butyrylcholinesterase K variant and apolipoprotein E4 genes do not act in synergy in Finnish late-onset Alzheimer’s disease patients. Neurosci Lett 250:69–71CrossRefPubMed

Holmes C, Ballard C, Lehmann D, David Smith A, Beaumont H, Day IN, NadeemKhan M, Lovestone S, McCulley M, Morris CM, Munoz DG, O’Brien K, Russ C, Del Ser T, Warden D (2005) Rate of progression of cognitive decline in Alzheimer’s disease: effect of butyrylcholinesterase K gene variation. J Neurol Neurosurg Psychiatry 76:640–643CrossRefPubMed

Huey ED, Putnam KT, Grafman J (2006) A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 66:17–22CrossRefPubMed

Jensen FS, Nielsen LR, Schwartz M (1996) Detection of the plasma cholinesterase K variant by PCR using an amplification-created restriction site. Hum Hered 46:26–31CrossRefPubMed

Ki CS, Na DL, Kim JW, Kim HJ, Kim DK, Yoon BK (1999) No association between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer’s Disease. Am J Med Genet 88:113–115CrossRefPubMed

Kim KW, Jhoo JH, Lee JH, Lee KU, Lee DY, Youn JC, Youn JY, Woo JI (2001) Neither the butyrylcholinesterase K variant nor transferrin C2 variant confers a risk for Alzheimer’s Disease in Koreans. J Neural Transm 108:1159–1166CrossRefPubMed

Lee DW, Liu HC, Chi CW, Hong CJ (2000) No association between butyrylcholinesterase K-variant and Alzheimer Disease in Chinese. Am J Med Genet 96:167–169CrossRefPubMed

Lehmann DJ, Johnston C, Smith AD (1997) Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer’s Disease. Hum Mol Genet 6:1933–1936CrossRefPubMed

Maetzler W, Keller S, Michelis J, Koehler N, Stransky E, Becker C, Schulte C, Melms A, Gasser T, Berg D (2009) No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases. Neurobiol Dis 35:296–301CrossRefPubMed

Mateo I, Llorca J, Infante J, Rodríguez-Rodríguez E, Berciano J, Combarros O (2008) Gene-gene interaction between 14-3-3 zeta and butyrylcholinesterase modulates Alzheimer’s disease risk. Eur J Neurol 15:219–222CrossRefPubMed

McIlroy SP, Crawford VL, Dynan KB, McGleenon BM, Vahidassr MD, Lawson JT, Passmore AP (2000) Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer’s disease in Northern Ireland. J Med Genet 37:182–185CrossRefPubMed

McKeith IG, O’Brien KK, Morris CM, Perry EK (2003) Butyrylcholinesterase and dementia with Lewy bodies: involvement in symptom progression and treatment response. In: Giacobini E (ed) Butyrylcholinesterase: its function and inhibitors. Martin Dunitz, London, pp 149–162

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical Diagnosis of Alzheimer’s Disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944PubMed

Mesulam M, Geula C (1994) Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 36:722–727CrossRefPubMed

Mullenbach R, Lagoda PJ, Welter C (1989) An efficient salt-chloroform extraction of DNA from blood and tissues. Trends Genet 5:391PubMed

Neary D, Snowden JS, Northern B, Goulding P (1988) Dementia of frontal lobe type. J Neurol Neurosurg Psychiatry 51:353–361CrossRefPubMed

O’Brien KK, Saxby BK, Ballard CG, Grace J, Harrington F, Ford GA, O’Brien JT, Swan AG, Fairbairn AF, Wesnes K, del Ser T, Edwardson JA, Morris CM, McKeith IG (2003) Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics 13:231–239CrossRefPubMed

Panegyres PK, Mamotte CD, Vasikaran SD, Wilton S, Fabian V, Kakulas BA (1999) Butyrycholinesterase K variant and Alzheimer’s disease. J Neurol 246:369–370CrossRefPubMed

Perry EK, Perry RH, Blessed G, Tomlinson BE (1978) Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 4:273–277CrossRefPubMed

Piccardi M, Congiu D, Squassina A, Manconi F, Putzu FP, Mereu RM, Chillotti C, Del Zompo M (2007) Alzheimer disease: Case-control association study of polymorphisms in ACHE, CHAT, and BCHE genes in a Sardinian sample. Am J Med Genet 144B:895–899CrossRefPubMed

Podoly E, Bruck T, Diamant S, Melamed-Book N, Weiss A, Huang Y, Livnah O, Langermann S, Wilgus H, Soreq H (2008) Human recombinant butyrylcholinesterase purified from the milk of transgenic goats interacts with beta-amyloid fibrils and suppresses their formation in vitro. Neurodegener Dis 5:232–236CrossRefPubMed

Podoly E, Shalev DE, Shenhar-Tsarfaty S, Bennett ER, Ben Assayag E, Wilgus H, Livnah O, Soreq H (2009) The butyrylcholinesterase K variant confers structurally derived risks for Alzheimer pathology. J Biol Chem 284:17170–17179CrossRefPubMed

Raygani AV, Zahrai M, Soltanzadeh A, Doosti M, Javadi E, Pourmotabbed T (2004) Analysis of association between Butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer’s Disease. Neurosci Lett 371:142–146CrossRefPubMed

Scacchi R, De Bernardini L, Mantuano E, Donini LM, Vilardo T, Corbo RM (1995) Apolipoprotein E (APOE) allele frequencies in late-onset sporadic Alzheimer’s disease (AD), mixed dementia and vascular dementia: lack of association of epsilon 4 allele with AD in Italian octogenarian patients. Neurosci Lett 201:231–234CrossRefPubMed

Scacchi R, Gambina G, Moretto G, Corbo RM (2008) Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer’s disease and relationships with response to treatment with Donepezil and Rivastigmine. Am J Med Genet B Neuropsychiatr Genet 150B:502–507

Singleton AB, Smith G, Gibson AM, Woodward R, Perry RH, Ince PG, Edwardson JA, Morris CM (1998) No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer’s Disease. Hum Mol Genet 7:937–939CrossRefPubMed

Sodeyama N, Yamada M, Itoh Y, Otomo E, Suematsu N, Matsushita M (1999) Association between butyrylcholinesterase K variant and the Alzheimer type neuropathological changes in apolipoprotein E epsilon4 carriers older than 75 years. J Neurol Neurosurg Psychiatry 67:693–694CrossRefPubMed

Tilley L, Morgan K, Grainger J, Marsters P, Morgan L, Lowe J, Xuereb J, Wischik C, Harrington C, Kalsheker N (1999) Evaluation of polymorphisms in the presenilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer’s disease. Eur J Hum Genet 7:659–663CrossRefPubMed

Whenam PR, Price WH, Blandell G (1991) Apolipoprotein E genotyping by one-stage PCR. Lancet 337:1158–1159

Wiebusch H, Poirier J, Sévigny P, Schappert K (1999) Further evidence for a synergistic association between APOE e4 and BCHE-K in confirmed Alzheimer’s Disease. Human Genet 104:158–163CrossRef

Yamamoto Y, Yasuda M, Mori E, Maeda K (1999) Failure to confirm a synergistic effect between the K-variant of the butyrylcholinesterase gene and the e4 allele of the apolipoprotein gene in Japanese patients with Alzheimer’s Disease. J Neurol Neurosurg Psychiatry 67:94–96CrossRefPubMed

Titel: BuChE K variant is decreased in Alzheimer’s disease not in fronto-temporal dementia
verfasst von: Alessandra Bizzarro
V. Guglielmi
R. Lomastro
A. Valenza
A. Lauria
C. Marra
M. C. Silveri
F. D. Tiziano
C. Brahe
C. Masullo
Publikationsdatum: 01.03.2010
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 3/2010
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-009-0358-y

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

Cognition in multiple system atrophy: neuropsychological profile and interaction with mood

Cholinergic dysfunction and amnesia in patients with Wernicke–Korsakoff syndrome: a transcranial magnetic stimulation study

Effects of amantadine on circulating neurotransmitters in healthy subjects

Erythropoietin concentration in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis

Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson’s disease patients with wearing-off: efficacy, safety and feasibility—an open-label, 6-week study